Lipomatosis, Multiple disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

FML MCID: LPM012 MIFTS: 64	Lipomatosis, Multiple (FML) Categories: Cancer diseases, Genetic diseases, Metabolic diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Lipomatosis, Multiple

MalaCards integrated aliases for Lipomatosis, Multiple:

Name: Lipomatosis, Multiple ⁵⁷ ²⁹ ⁷³

Lipoma ⁵⁷ ¹² ²⁹ ⁵⁵ ¹⁵ ⁷³

Lipomatosis, Familial Multiple ⁵⁷ ¹²

Familial Multiple Lipomatosis ⁵³ ⁵⁹

Benign Lipomatous Tumor ¹² ⁷³

Multiple Lipomatosis ¹² ⁵³

Lipomatous Neoplasm ¹² ⁷³

Lipomatosis, Familial Multiple; Fml ⁵⁷

Benign Tumor of Adipose Tissue ¹²

Neoplasms, Adipose Tissue ⁴⁴

Tumor of Adipose Tissue ¹²

Lipomatous Tumor ¹²

Lipoma; Lipo ⁵⁷

Lipo ⁵⁷

Fml ⁵⁷

Characteristics:

OMIM:

⁵⁷

Inheritance:
autosomal dominant

HPO:

³²

lipomatosis, multiple:
Inheritance autosomal dominant inheritance

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Metabolic diseases Genetic diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³³ ³⁴

Endocrine, nutritional and metabolic diseases

Metabolic disorders

Other metabolic disorders

Lipomatosis, not elsewhere classified

Neoplasms

Benign neoplasms

Benign lipomatous neoplasm

Benign lipomatous neoplasm, unspecified

Orphanet: ⁵⁹

Rare skin diseases

External Ids:

OMIM ⁵⁷ 151900

Disease Ontology ¹² DOID:3315

ICD10 ³³ D17 D17.9

ICD9CM ³⁵ 214 214.9

MeSH ⁴⁴ D008067 D018205

NCIt ⁵⁰ C3192 C4248 C4502

SNOMED-CT ⁶⁸ 46720004 93163002

Orphanet ⁵⁹ ORPHA199276

UMLS via Orphanet ⁷⁴ C3489413

ICD10 via Orphanet ³⁴ E88.2

MedGen ⁴² C3489413

UMLS ⁷³ C0023798 C0206631 C0346118 more

Sources

Summaries for Lipomatosis, Multiple

NIH Rare Diseases : ⁵³ Familial multiple lipomatosis (FML) is a rare condition that is characterized by multiple lipomas on the trunk and extremities. As the name suggests, FML is diagnosed when multiple lipomatosis occurs in more than one family member, often over several generations. The lipomas associated with FML are usually painless, but may impact quality of life as they can be numerous and large. Although the condition appears to be passed down through families in an autosomal dominant manner, the underlying genetic cause is currently unknown. Treatment is based on the signs and symptoms present in each person. Surgical excision may be necessary if the tumors interfere with movement and/or daily life.

MalaCards based summary : Lipomatosis, Multiple, also known as lipoma, is related to skin lipoma and spindle cell lipoma. An important gene associated with Lipomatosis, Multiple is HMGA2 (High Mobility Group AT-Hook 2), and among its related pathways/superpathways are p53 Signaling and Chromatin Regulation / Acetylation. The drugs Afinitor and Avastin have been mentioned in the context of this disorder. Affiliated tissues include colon, skin and bone, and related phenotypes are macrocephaly and seizures

Disease Ontology : ¹² A cell type benign neoplasm that is composed of lipocytes.

OMIM : ⁵⁷ Familial multiple lipomatosis is a rare autosomal dominant disorder characterized by numerous encapsulated lipomas on the trunk and extremities (Keskin et al., 2002). (151900)

Wikipedia : ⁷⁶ A lipoma is a benign tumor made of fat tissue. They are generally soft to the touch, movable, and... more...

Sources

Related Diseases for Lipomatosis, Multiple

Diseases in the Lipomatosis family:

Lipomatosis, Multiple

Diseases related to Lipomatosis, Multiple via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 448)

#	Related Disease	Score	Top Affiliating Genes
1	skin lipoma	33.8	PTEN HMGA2
2	spindle cell lipoma	33.7	MDM2 DES CDK4
3	chondroid lipoma	33.5	MEN1 MDM2 FUS CDK4
4	infiltrating lipoma	33.4	MDM2 LPP HMGA2 CDK4
5	well-differentiated liposarcoma	32.5	MDM2 HMGA2 CDK4
6	pleomorphic lipoma	32.1	MDM2 HMGA2
7	atypical lipomatous tumor	32.0	MDM2 HMGA2 FUS CDK4
8	liposarcoma	30.6	MDM2 HMGA2 FUS DES CDK4
9	lipomatosis	30.4	UCP1 PTEN MEN1 HMGA2
10	lipoblastoma	30.3	MDM2 CDK4
11	pleomorphic liposarcoma	29.9	MDM2 DES
12	myxoid liposarcoma	29.9	MDM2 HMGA2 FUS CDK4
13	hemangiopericytoma, malignant	29.8	DES MDM2
14	dedifferentiated liposarcoma	29.8	MDM2 HMGA2 DES CDK4
15	infiltrating angiolipoma	29.8	MDM2 CDK4
16	spindle cell liposarcoma	29.7	MDM2 CDK4
17	cellular myxoid liposarcoma	29.6	MDM2 FUS CDK4
18	leiomyosarcoma	29.5	MDM2 DES CDK4
19	lipomatosis, multiple symmetric	12.5
20	nasopalpebral lipoma-coloboma syndrome	12.4
21	chest wall lipoma	12.3
22	pleural lipoma	12.3
23	spinal cord lipoma	12.3
24	lipoma of spermatic cord	12.3
25	tendon sheath lipoma	12.3
26	hemihyperplasia-multiple lipomatosis syndrome	12.3
27	thymus lipoma	12.3
28	large intestine lipoma	12.2
29	gallbladder lipoma	12.2
30	extrahepatic bile duct lipoma	12.2
31	central nervous system lipoma	12.2
32	epicardium lipoma	12.2
33	lipoma of colon	12.2
34	corpus callosum lipoma	12.2
35	endobronchial lipoma	12.1
36	breast lipoma	12.1
37	axillary lipoma	12.1
38	lumbosacral lipoma	12.1
39	esophageal lipoma	12.1
40	liver lipoma	12.1
41	internal auditory canal lipoma	12.1
42	lipoma of the rectum	12.1
43	classic type lipoma	12.1
44	paratesticular lipoma	12.1
45	cleft, median, of upper lip with polyps of facial skin and nasal mucosa	12.1
46	lipoma of the conjunctiva	12.0
47	kidney lipoma	12.0
48	external auditory meatus lipoma	12.0
49	cerebral hemisphere lipoma	12.0
50	cowden syndrome 1	11.9

Graphical network of the top 20 diseases related to Lipomatosis, Multiple:

Sources

Symptoms & Phenotypes for Lipomatosis, Multiple

Symptoms via clinical synopsis from OMIM:

⁵⁷

Skin:
lipomatosis

Lab:
frequent rearrangements at 12q13 or 12q14

Clinical features from OMIM:

151900

Human phenotypes related to Lipomatosis, Multiple:

⁵⁹ ³² (show all 25)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	macrocephaly ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0000256
2	seizures ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0001250
3	cerebral calcification ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0002514
4	bowing of the long bones ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0006487
5	delayed speech and language development ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0000750
6	peripheral neuropathy ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0009830
7	lipodystrophy ⁵⁹ ³²	hallmark (90%)	Very frequent (99-80%)	HP:0009125
8	ventriculomegaly ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0002119
9	hyperlipidemia ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0003077
10	accelerated skeletal maturation ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0005616
11	increased adipose tissue ⁵⁹ ³²	hallmark (90%)	Very frequent (99-80%)	HP:0009126
12	hypoplasia of the corpus callosum ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0002079
13	insulin resistance ⁵⁹ ³²	hallmark (90%)	Very frequent (99-80%)	HP:0000855
14	arachnoid cyst ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0100702
15	coloboma ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0000589
16	overgrowth ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0001548
17	medulloblastoma ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0002885
18	functional intestinal obstruction ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0005249
19	premature eruption of permanent teeth ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0006337
20	chorioretinitis ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0012424
21	multiple lipomas ³²			HP:0001012
22	abnormality of the tricuspid valve ⁵⁹		Occasional (29-5%)
23	keratocystic odontogenic tumor ⁵⁹		Occasional (29-5%)
24	odontogenic keratocysts of the jaw ³²	occasional (7.5%)		HP:0010603
25	abnormal tricuspid valve morphology ³²	occasional (7.5%)		HP:0001702

MGI Mouse Phenotypes related to Lipomatosis, Multiple:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.97	ALX3 CDK4 DES LPP MDM2 MEN1
2	homeostasis/metabolism	MP:0005376	9.81	ALX3 CDK4 DES LPP MDM2 MEN1
3	digestive/alimentary	MP:0005381	9.73	ALX3 CDK4 MDM2 MEN1 MNX1 PTEN
4	mortality/aging	MP:0010768	9.61	ALX3 CDK4 DES LPP MDM2 MEN1
5	muscle	MP:0005369	9.1	CDK4 DES MDM2 MEN1 MNX1 PTEN

Sources

Drugs & Therapeutics for Lipomatosis, Multiple

FDA approved drugs:

(show all 8)

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Afinitor ¹⁸ ⁴⁹	EVEROLIMUS	Novartis	March 2009
FDA Label: Afinitor Disease/s that Drug Treats:renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumors/ hormone receptor-positive, HER2-negative breast cancer Indications and Usage: ¹⁸ AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5) DrugBank Targets: ¹⁶ Serine/threonine-protein kinase mTOR Mechanism of Action: ¹⁸ Target: mTOR Action: inhibitor FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of thePI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellularprotein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition ofmTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiationfactor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate ofmTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independentactivation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) andreduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shownto reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitrostudies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activityof everolimus in a synergistic manner.Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.
2	Avastin ¹⁸ ⁴⁹	BEVACIZUMAB	Genentech	July 2009
FDA Label: Avastin Disease/s that Drug Treats:renal cell carcinoma & Colorectal Cancer Indications and Usage: ¹⁸ Avastin is a vascular endothelial growth factor-specific angiogenesisinhibitor indicated for the treatment of: Metastatic colorectal cancer, with intravenous 5-fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- orfluoropyrimidine-oxaliplatin-based chemotherapy for second-linetreatment in patients who have progressed on a first-line Avastincontainingregimen. (1.1) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxelfor first line treatment of unresectable, locally advanced, recurrent ormetastatic disease. (1.2) Glioblastoma, as a single agent for adult patients with progressive diseasefollowing prior therapy. (1.3)-Effectiveness based on improvement in objective response rate. No dataavailable demonstrating improvement in disease-related symptoms orsurvival with Avastin. Metastatic renal cell carcinoma with interferon alfa (1.4) Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxeland topotecan in persistent, recurrent, or metastatic disease. (1.5) Platinum-resistant recurrent epithelial ovarian, fallopian tube or primaryperitoneal cancer, in combination with paclitaxel, pegylated liposomaldoxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of coloncancer. (1.1) DrugBank Targets: ¹⁶ 1. Vascular endothelial growth factor A;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c Mechanism of Action: ¹⁸ Target: VEGF Action: inhibitor FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR)697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction700 of microvascular growth and inhibition of metastatic disease progression
3	Doxil ¹⁸ ⁴⁹	DOXORUBICIN HYDROCHLORIDE	Alza	June 1999
FDA Label: Doxil Disease/s that Drug Treats:ovarian cancer that is refractory to other first-line therapies Indications and Usage: ¹⁸ DOXIL is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer (1.1)After failure of platinum-based chemotherapy. AIDS-related Kaposiâs Sarcoma (1.2)After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma (1.3)In combination with bortezomib in patients who have not previouslyreceived bortezomib and have received at least one prior therapy. DrugBank Targets: ¹⁶ 1. DNA;2. DNA topoisomerase 2-alpha Mechanism of Action: ¹⁸ Target: nucleic acidsynthesis Action: inhibitor FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action ofdoxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acidsynthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclearReference ID: 373359617 chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, andinduction of mutagenesis and chromosomal aberrations.
4	Marqibo ¹⁸ ⁴⁹	VINCRISTINE SULFATE	Talon Therapeutics	August 2012
FDA Label: Marqibo Disease/s that Drug Treats:Ph- acute lymphoblastic leukemia Indications and Usage: ¹⁸ Marqibo is a vinca alkaloid indicated for the treatment of adult patients withPhiladelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)in second or greater relapse or whose disease has progressed following two ormore anti-leukemia therapies. This indication is based on overall responserate. Clinical benefit such as improvement in overall survival has not beenverified (1.1). DrugBank Targets: ¹⁶ 1. Tubulin beta chain;2. Tubulin alpha-4A chain Mechanism of Action: ¹⁸ Target: tubulin Action: alters polymerization equilibrium FDA: Marqibo is a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate.Non-liposomal vincristine sulfate binds to tubulin, altering the tubulin polymerization equilibrium, resulting inaltered microtubule structure and function. Non-liposomal vincristine sulfate stabilizes the spindle apparatus,preventing chromosome segregation, triggering metaphase arrest and inhibition of mitosis.
5	DuoNeb ¹⁸	ALBUTEROL SULFATE; IPRATROPIUM BROMIDE	Dey Laboratories	March 2001
FDA Label: DuoNeb Disease/s that Drug Treats:Bronchospasm associated with COPD for patients who require more than one bronchodilator Indications and Usage: ¹⁸ DuoNebÂ® - (Ipratropium Bromide 0.5 mg/Albuterol Sulfate 3.0 mg) - Inhalation Solution - Equivalent to 2.5 mg albuterol base - DESCRIPTION - The active components in DuoNebÂ® Inhalation Solution are albuterol sulfate and ipratropium bromide. Albuterol sulfate, is a salt of racemic albuterol and a relatively selective Î²2-adrenergic bronchodilator chemically described as Î±1-[(tert-butylamino)methyl]-4-hydroxy-mxylene-Î±, Î±'-diol sulfate (2:1) (salt). It has a molecular weight of 576.7 and the empirical formula is (C13H21NO3)2H2SO4. It is a white crystalline powder, soluble in water and slightly soluble in ethanol. The World Health Organization recommended name for albuterol base is salbutamol.Ipratropium bromide is an anticholinergic bronchodilator chemically described as 8- azoniabicyclo [3.2.1]-octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8methyl-8-(1- methylethyl)-, bromide, monohydrate (endo, syn)-, (Â±)-; a synthetic quaternary ammonium compound, chemically related to atropine. It has a molecular weight of 430.4 and the empirical formula is C20H30BrNO3H2O. It is a white crystalline substance, freely soluble in water and lower alcohols, and insoluble in lipophilic solvents such as ether, chloroform, and fluorocarbons. DrugBank Targets: ¹⁶ ¹⁶ Muscarinic acetylcholine receptor M1\|Muscarinic acetylcholine receptor M2\|Muscarinic acetylcholine receptor M3\|Beta-2 adrenergic receptor\|Beta-1 adrenergic receptor Mechanism of Action: ¹⁸ Target: beta2-adrenergic\|acetylcholine Action: bronchodilator\|blocker of physiologic action FDA: -
6	Rayos ¹⁸	PREDNISONE	Horizon Pharma	July of 2012
FDA Label: Rayos Disease/s that Drug Treats:certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions Indications and Usage: ¹⁸ RAYOS is a corticosteroid indicated * as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation (1) * for the treatment of certain endocrine conditions (1) * for palliation of certain neoplastic conditions (1) DrugBank Targets: ¹⁶ Glucocorticoid receptor\|Corticosteroid 11-beta-dehydrogenase isozyme 1 Mechanism of Action: ¹⁸ Target: many organ systems Action: anti-inflammatory FDA: Naturally occurring corticosteroids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, such as prednisone, are primarily used for their potent antiinflammatory effects in disorders of many organ systems. Corticosteroids, such as prednisone, cause profound and varied metabolic effects. In addition, they modify the bodyâs immune responses to diverse stimuli. Prednisone is a synthetic adrenocortical steroid drug with predominantly corticosteroid properties. Some of these properties reproduce the physiological actions of endogenous glucocorticosteroids, but others do not necessarily reflect any of the adrenal hormonesâ normal functions; they are seen only after administration of large therapeutic doses of the drug. The pharmacological effects of prednisone which are due to its corticosteroid properties include: promotion of gluconeogenesis; increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation of fat synthesis and storage; increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion. Depressed production of eosinophils and lymphocytes occurs, but erythropoiesis and production of polymorphonuclear leukocytes are stimulated. Inflammatory processes (edema, fibrin deposition, capillary dilatation, migration of leukocytes and phagocytosis) and the later stages of wound healing (capillary proliferation, deposition of collagen, cicatrization) are inhibited. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension.
7	Vibativ ¹⁸	* TELAVANCIN * TELAVANCIN HYDROCHLORIDE	Theravance	June 2013
FDA Label: Vibativ Disease/s that Drug Treats:hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus Indications and Usage: ¹⁸ VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: * Complicated skin and skin structure infections (cSSSI) (1.1) * Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus. VIBATIV should be reserved for use when alternative treatments are not suitable. (1.2) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: late-stage peptidoglycan precursors Action: inhibits cell wall biosynthesis FDA: Telavancin is an antibacterial drug [see Clinical Pharmacology (12.4)]. Telavancin inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II. Telavancin also binds to the bacterial membrane and disrupts membrane barrier function.
8	Zyflo ¹⁸	ZILEUTON	Abbott Laboratories	January 1997
FDA Label: Zyflo Disease/s that Drug Treats:asthma Indications and Usage: ¹⁸ ZYFLO is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. DrugBank Targets: ¹⁶ Arachidonate 5-lipoxygenase Mechanism of Action: ¹⁸ Target: 5-lipoxygenase (5-LO) Action: inhibitor FDA: Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTC4, LTD4, and LTE4) formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Sulfido-peptide leukotrienes (LTC4, LTD4, LTE4, also known as the slow-releasing substances of anaphylaxis) and LTB4, a chemoattractant for neutrophils and eosinophils, can be measured in a number of biological fluids including bronchoalveolar lavage fluid (BALF) from asthmatic patients. Zileuton is an orally active inhibitor of ex vivo LTB4 formation in several species, including dogs, monkeys, rats, sheep, and rabbits. Zileuton inhibits arachidonic acidinduced ear edema in mice, neutrophil migration in mice in response to polyacrylamide gel, and eosinophil migration into the lungs of antigen-challenged sheep. Zileuton inhibits leukotriene-dependent smooth muscle contractions in vitro in guinea pig and human airways. The compound inhibits leukotriene-dependent bronchospasm in antigen and arachidonic acid-challenged guinea pigs. In antigen-challenged sheep, zileuton inhibits late-phase bronchoconstriction and airway hyperreactivity. In humans, pretreatment with zileuton attenuated bronchoconstriction caused by cold air challenge in patients with asthma.

Drugs for Lipomatosis, Multiple (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Prednisolone phosphate

Approved, Vet_approved

Phase 1, Phase 2

302-25-0

Methylprednisolone

Approved, Vet_approved

Phase 1, Phase 2

83-43-2

6741

Synonyms:

(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione

(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione

(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one

(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione

.DELTA.1-6.alpha.-Methylhydrocortisone

11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione

11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione

11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione

11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione

121673-01-6

1-dehydro-6alpha-Methylhydrocortisone

1-Dehydro-6alpha-methylhydrocortisone

1-dehydro-6a-Methylhydrocortisone

1-dehydro-6α-methylhydrocortisone

4-08-00-03498 (Beilstein Handbook Reference)

46436_FLUKA

46436_RIEDEL

570-35-4

6 Methylprednisolone

6.alpha.-Methylprednisolone

6923-42-8

6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione

6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione

6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione

6alpha-Methylprednisolone

6-alpha-Methylprednisolone

6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione

6-Methylprednisolone

6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione

83-43-2

AC1L1N7A

Artisone-wyeth

Artisone-Wyeth

Besonia

Bio-0658

BPBio1_000174

BRD-K35240538-001-03-1

BRN 2340300

BSPBio_000158

CHEBI:6888

CHEMBL650

CID6741

CPD000058330

D00407

D008775

DB00959

delta(1)-6alpha-Methylhydrocortisone

Delta(1)-6alpha-Methylhydrocortisone

delta(1)-6a-Methylhydrocortisone

delta(sup 1)-6-alpha-Methylhydrocortisone

Depo-Medrol (acetate)

Dopomedrol

EINECS 201-476-4

Esametone

Firmacort

HMS1568H20

HMS2090B13

HSDB 3127

Lemod

LMST02030178

LS-118498

M0639_SIGMA

M1665

Medesone

Medixon

Medlone 21

Medrate

Medric acid

Medrol

Medrol (TN)

Medrol adt pak

Medrol Adt Pak

Medrol dosepak

Medrol Dosepak

Medrol, Solu-Medrol, Medrone, Methylprednisolone

Medrone

MEPRDL

Mesopren

Metastab

Methyleneprednisolone

Methylprednisolon

methylprednisolone

Methylprednisolone

Methylprednisolone (JP15/USP/INN)

Methylprednisolone [USAN:INN:BAN:JAN]

Methylprednisolone, 6-alpha

Methylprednisolonum

Methylprednisolonum [INN-Latin]

methylprenisolone

Metilbetasone

Metilprednisolona

Metilprednisolona [INN-Spanish]

Metilprednisolone

Metilprednisolone [Dcit]

Metilprednisolone [DCIT]

Metipred

Metrisone

Metrocort

Metysolon

MLS000028541

MLS001148159

MLS002207191

Moderin

MolPort-002-528-554

NCGC00022735-03

NCI60_001657

Nirypan

Noretona

NSC19987

NSC-19987

Predni N Tablinen

Prednol- L

Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)

Prestwick_622

Prestwick0_000279

Prestwick1_000279

Prestwick2_000279

Prestwick3_000279

Promacortine

Reactenol

S1733_Selleck

SAM002589984

Sieropresol

SMR000058330

Solomet

SPBio_002377

Summicort

Suprametil

U 7532

UNII-X4W7ZR7023

Urbason

Urbasone

Wyacort

ZINC03875560

δ(1)-6a-methylhydrocortisone

δ(1)-6α-methylhydrocortisone

Prednisolone

Approved, Vet_approved

Phase 1, Phase 2

50-24-8

5755

Synonyms:

(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione

(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione

(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione

.DELTA.1-Cortisol

.DELTA.1-Dehydrocortisol

.DELTA.1-Dehydrohydrocortisone

.DELTA.1-Hydrocortisone

.delta.-Cortef

.delta.-Stab

1,2-Dehydrohydrocortisone

1,4-Pregnadiene-11b,17a,21-triol-3,20-dione

1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione

1,4-pregnadiene-11β,17α,21-triol-3,20-dione

1,4-Pregnadiene-11β,17α,21-triol-3,20-dione

1,4-Pregnadiene-3,20-dione-11b,17a,21-triol

1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol

1,4-pregnadiene-3,20-dione-11β,17α,21-triol

1,4-Pregnadiene-3,20-dione-11β,17α,21-triol

1-Dehydrocortisol

1-Dehydrohydrocortisone

3,20-dioxo-11b,17a,21-Trihydroxy-1,4-pregnadiene

3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene

3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene

46656_FLUKA

46656_RIEDEL

50-24-8

58201-11-9

8056-11-9

AC-1773

AC1L1L2E

Ak-Pred

Ak-Tate

Alphadrol

Articulose-50

Bio-0666

BPBio1_000164

BRD-K98039984-001-03-0

BRN 1354103

BSPBio_000148

Bubbli-Pred

C07369

CCRIS 980

CHEBI:8378

CHEMBL131

CID5755

Codelcortone

Co-Hydeltra

CO-Hydeltra

component of Ataraxoid

component of K-Predne-Dome

Cordrol

Cortalone

Cotogesic

Cotolone

CPD000718761

D00472

D011239

DB00860

Decaprednil

Decortin H

Delcortol

Delta F

delta(1)-Cortisol

delta(1)-Dehydrocortisol

Delta(1)-Dehydrocortisol

delta(1)-Dehydrohydrocortisone

Delta(1)-dehydrohydrocortisone

Delta(1)-Dehydrohydrocortisone

delta(1)-Hydrocortisone

Delta(1)-Hydrocortisone

delta(sup 1)-Cortisol

delta(sup 1)-Dehydrocortisol

delta(sup 1)-Dehydrohydrocortisone

delta(sup 1)-Hydrocortisone

Delta-Cortef

Delta-Cortef (TN)

Deltacortenol

Deltacortril

Deltacortril Enteric

delta-dehydrocortisol

delta-dehydrohydrocortisone

Delta-Ef-Cortelan

delta-hydrocortisone

Deltahydrocortisone

Deltasolone

Delta-stab

Delta-Stab

Deltisilone

Depo-Medrol

Derpo Pd

Derpo PD

Dexa-Cortidelt hostacortin H

Dexa-Cortidelt Hostacortin H

Di adreson F

Di Adreson F

Di-adreson F

Di-Adreson F

Di-adreson-F

DiAdresonF

Di-Adreson-F

Dicortol

Donisolone

Dydeltrone

Eazolin D

Econopred

Econopred Plus

EINECS 200-021-7

Erbacort

Erbasona

Estilsona

Fernisolone

Fernisolone P

Fernisolone-P

Flamasone

HMS1568H10

HMS2090J05

Hostacortin H

HSDB 3385

Hydeltra

Hydeltrasol

Hydeltra-Tba

Hydeltrone

Hydrodeltalone

Hydrodeltisone

Hydroretrocortin

Hydroretrocortine

Inflamase Forte

Inflamase Mild

I-Pred

K 1557

Key-Pred

Klismacort

Lentosone

Lite Pred

LMST02030179

LS-7669

Medrol

Medrol Acetate

Metacortandralone

Methylprednisolone acetate

Methylprednisolone Acetate

Meticortelone

Meti-Derm

Metreton

MLS001304083

MLS002154250

MLS002207037

MolPort-002-507-147

M-Predrol

NCGC00179649-01

Neo-Delta-Cortef

Nisolone

Nor-Pred T.B.A.

NSC 9120

NSC9120

NSC9900

Ocu-Pred

Ocu-Pred Forte

Ophtho-Tate

Orapred

P0152_SIGMA

P0637

P6004_SIGMA

Panafcortelone

Paracortol

Paracotol

Pediapred

Poly-Pred

PRDL

Precortalon

Precortancyl

Precortilon

Precortisyl

Pred Forte

Pred Mild

Predair

Predair A

Predair Forte

Predalone 50

Predalone T.B.A.

Predate

Predate Tba

Predate-50

Predcor-25

Predcor-50

Predcor-Tba

PRED-G

Predisolone sodium phosphate

Predisolone Sodium Phosphate

Predne-Dome

Prednelan

Prednicen

Predni-Dome

Predniliderm

Predniretard

Prednis

Prednisolona

Prednisolona [INN-Spanish]

prednisolone

Prednisolone (anhydrous)

Prednisolone (JP15/USP/INN)

Prednisolone [INN:BAN:JAN]

Prednisolone acetate

Prednisolone Acetate

Prednisolone sodium phosphate

Prednisolone Sodium Phosphate

Prednisolone tebutate

Prednisolone Tebutate

Prednisolonum

Prednisolonum [INN-Latin]

Predonin

Predonine

Prelone

Prenolone

Prestwick_404

Prestwick0_000274

Prestwick1_000274

Prestwick2_000274

Prestwick3_000274

Rolisone

S1737_Selleck

SAM002264639

Scherisolon

SMR000718761

Solone

SPBio_002367

Steran

Sterane

Sterolone

Supercortisol

Ulacort

Ultra Pred

Ultracorten H

Ultracortene H

Ultracortene-H

Ultracortene-hydrogen

Ultracortene-Hydrogen

UNII-9PHQ9Y1OLM

ZINC03833821

δ(1)-dehydrocortisol

δ(1)-dehydrohydrocortisone

δ(1)-hydrocortisone

Methylprednisolone hemisuccinate

Approved

Phase 1, Phase 2

2921-57-5

Cortisone acetate

Approved, Investigational

Phase 1, Phase 2

1950-04-4, 50-04-4

5745

Isoproterenol

Approved, Investigational

Phase 1, Phase 2

7683-59-2

3779

Synonyms:

(-)-Isoproterenol hydrochloride

(+)-Isoprenaline

(+-)-Isoprenaline

(+)-Isoproterenol

(+-)-Isoproterenol

(±)-isoprenaline

(±)-isoproterenol

(S)-(+)-Isoproterenol

(S)-Isoprenaline

(S)-Isoproterenol

.alpha.-(Isopropylaminomoethyl)protocatechuyl alcohol

1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol

1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol

1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)- (9CI)

1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)- (9CI)

149-53-1

2964-04-7

3,4-Dihydroxy-.alpha.-(isopropylaminomethyl)-benzyl alcohol

3,4-Dihydroxy-.alpha.-[(isopropylamino)methyl]benzyl alcohol

3,4-Dihydroxy-a-[(isopropylamino)methyl]benzyl alcohol

3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol

3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol

3,4-Dihydroxy-α-[(isopropylamino)methyl]benzyl alcohol

3-13-00-02387 (Beilstein Handbook Reference)

4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol

4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol

4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol

46388-38-9

7683-59-2

a-(Isopropylaminomethyl)protocatechuyl alcohol

AC1L1GOZ

AC1Q1QBS

Aerolone

Aleudrin

Aleudrine

alpha-(Isopropylaminomethyl)protocatechuyl alcohol

Aludrin

Aludrine

Asiprenol

Asmalar

Assiprenol

Bellasthman

BRN 2213857

Bronkephrine

BSPBio_002208

C07056

CCRIS 3081

CHEMBL434

CID3779

D08090

DB01064

Dihydroxyphenylethanolisopropylamine

d-Isoprenaline

d-Isopropylarterenol

d-Isoproterenol

DivK1c_000894

DL(+-)-Isoproterenol

dl-Ipr

dl-Isadrine

dl-Isopropylnoradrenaline

DL-Isopropylnorepinephrine

dl-N-Isopropylnoradrenaline

d-N-Isopropylnorepinephrine

EINECS 231-687-7

Epinephrine isopropyl homolog

Epinephrine Isopropyl Homolog

Euspiran

HMS2089A12

Hydrochloride, isoproterenol

ICI 46399

IDI1_000894

IPA

Isadrin

Isadrine

Isonorene

Isonorin

Isoprenalin

Isoprenalina

Isoprenalina [INN-Spanish]

Isoprenaline

Isoprenaline (INN)

Isoprenaline hydrochloride

Isoprenalinum

Isoprenalinum [INN-Latin]

ISOPROP

Isopropydrin

Isopropyl noradrenaline

Isopropyladrenaline

Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol

Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol

Isopropylarterenol

Isopropylnoradrenaline

Isopropylnorepinephrine

isoproterenol

Isoproterenol

Isoproterenol [JAN]

Isoproterenol chloride

Isoproterenol Chloride

Isoproterenol HCl

Isoproterenol hydrochloride

Isoproterenol sulfate

Isoproterenolum

Isorenin

Isuprel

Isuprel Mistometer

Isupren

Izadrin

KBio1_000894

KBio2_001429

KBio2_003997

KBio2_006565

KBio3_001428

KBioGR_000427

KBioSS_001429

L000936

l-Isopropylnoradrenaline

L-Isopropylnoradrenaline

l-Isoproterenol

L-Isoproterenol

Lomupren

Lopac0_000711

LS-42866

LS-42868

LS-42869

Medihaler-Iso

Medihaler-ISO

MolPort-001-783-449

NCGC00015558-08

NCGC00025274-03

NCGC00025274-04

NCGC00162220-01

nchembio.307-comp1

nchembio801-comp2

nchembio882-comp6

Neodrenal

neo-Epinine

Neo-Epinine

NINDS_000894

N-Isopropyl-b-dihydroxyphenyl-b-hydroxyethylamine

N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine

N-Isopropylnoradrenaline

N-Isopropylnorepinephrine

N-isopropyl-β-dihydroxyphenyl-β-hydroxyethylamine

N-Isopropyl-β-dihydroxyphenyl-β-hydroxyethylamine

Noradrenaline, isopropyl

Norisodrine

Norisodrine Aerotrol

Novodrin

NSC 33791

NSC 9975

NSC33791

NSC9975

Oprea1_009434

PDSP1_001425

PDSP2_001409

Prestwick0_001097

Prestwick1_001097

Prestwick2_001097

Proternol

Racemic isoprenaline

Racemic isoproterenol

Respifral

Saventrine

SGCUT00015

SPBio_001042

SPBio_003057

Spectrum_000949

Spectrum2_001061

Spectrum3_000474

Spectrum4_000024

Spectrum5_000880

STOCK1N-00740

Sulfate, isoproterenol

to_000062

UNII-L628TT009W

Vapo-Iso

Vapo-N-iso

WIN 5162

WLN: QR BQ DYQ1MY1&1

α-(isopropylaminomethyl)protocatechuyl alcohol

deoxycholic acid

Approved

Phase 2,Phase 1

83-44-3

222528

Synonyms:

(3a,5a,12a)-3,12-DIHYDROXYCHOLAN-24-Oate

(3a,5a,12a)-3,12-DIHYDROXYCHOLAN-24-Oic acid

(3a,5b,12a)-3,12-Dihydroxycholan-24-Oate

(3a,5b,12a)-3,12-Dihydroxycholan-24-Oic acid

(3alpha,5alpha,12alpha)-3,12-DIHYDROXYCHOLAN-24-Oate

(3ALPHA,5ALPHA,12ALPHA)-3,12-DIHYDROXYCHOLAN-24-OIC ACID

(3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-Oate

(3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-Oic acid

(3α,5α,12α)-3,12-dihydroxycholan-24-Oate

(3α,5α,12α)-3,12-dihydroxycholan-24-Oic acid

(3α,5β,12α)-3,12-dihydroxycholan-24-Oate

(3α,5β,12α)-3,12-dihydroxycholan-24-oic acid

(3α,5β,12α)-3,12-dihydroxycholan-24-Oic acid

12beta-Isomer deoxycholic acid

3a,12a-Dihydroxy-5b-cholanate

3a,12a-Dihydroxy-5b-cholanic acid

3alpha,12alpha-Dihydroxy-5beta-cholanate

3alpha,12alpha-Dihydroxy-5beta-cholanic acid

3beta-Isomer deoxycholic acid

3α,12α-dihydroxy-5β-cholanate

3α,12α-dihydroxy-5β-cholanic acid

5alpha-Isomer deoxycholic acid

5b-Cholanic acid-3a,12a-diol

5b-Deoxycholate

5b-Deoxycholic acid

7a-Deoxycholate

7a-Deoxycholic acid

7alpha-Deoxycholate

7alpha-Deoxycholic acid

7-Deoxycholate

7-Deoxycholic acid

7α-deoxycholate

7α-deoxycholic acid

Acid, 5alpha-isomer deoxycholic

Acid, choleic

Acid, deoxycholic

Acid, desoxycholic

Acid, dihydroxycholanoic

Acid, lagodeoxycholic

Choleic acid

Cholerebic

Cholorebic

Degalol

Deoxycholatate

deoxycholate

Deoxycholate

Deoxy-cholate

Deoxycholate, sodium

Deoxycholatic acid

Deoxy-cholic acid

Deoxycholic acid, 12beta isomer

Deoxycholic acid, 12beta-isomer

Deoxycholic acid, 3beta isomer

Deoxycholic acid, 3beta-isomer

Deoxycholic acid, 5alpha isomer

Deoxycholic acid, 5alpha-isomer

Deoxycholic acid, disodium salt

Deoxycholic acid, magnesium (2:1) salt

Deoxycholic acid, monoammonium salt

Deoxycholic acid, monopotassium salt

Deoxycholic acid, monosodium salt

Deoxycholic acid, sodium salt, 12beta-isomer

Desoxycholate

desoxycholic acid

Desoxycholic acid

Desoxycholsaeure

Desoxycholsäure

Dihydroxycholanoic acid

Lagodeoxycholic acid

Sodium deoxycholate

Prednisolone hemisuccinate

Experimental

Phase 1, Phase 2

2920-86-7

Cortisone

Experimental

Phase 1, Phase 2

53-06-5

222786

Synonyms:

11-dehydro-17-hydroxycorticosterone

11-dehydro-17-Hydroxycorticosterone

17a,21-Dihydroxy-4-pregnene-3,11,20-trione

17alpha,21-Dihydroxy-4-pregnene-3,11,20-trione

17-Hydroxy-11-dehydrocorticosterone

17α,21-dihydroxy-4-pregnene-3,11,20-trione

4-Pregnene-17a,21-diol-3,11,20-trione

4-Pregnene-17alpha,21-diol-3,11,20-trione

4-pregnene-17α,21-diol-3,11,20-trione

4-Pregnene-17α,21-diol-3,11,20-trione

Adreson

Andreson

Anusol HC

Balneol-HC

beta-HC

Colocort

Compound e

Corlin

Cortadren

Cortandren

Cortef

Cortef acetate

Cortisal

Cortisate

Cortison

Cortisona

Cortisone acetate

Cortisonum

Cortistal

Cortivite

Cortogen

Cortone

Cortril

delta(4)-Pregnene-17a,21-diol-3,11,20-trione

Delta(4)-Pregnene-17alpha,21-diol-3,11,20-trione

Dermacort

Dricort

Flexicort

Florinef

Fludrocortisone acetate

Glycort

Hemsol-HC

Hi-cor

Incortin

Kendall'S compound

Kendall's compound e

Kendall's compound E

Kortison

Locoid

Locoid lipocream

Micort-HC

Nogenic HC

Orabase hca

Pandel

Pregn-4-en-17a,21-diol-3,11,20-trione

Pregn-4-en-17alpha,21-diol-3,11,20-trione

pregn-4-en-17α,21-diol-3,11,20-trione

Pregn-4-en-17α,21-diol-3,11,20-trione

Prestwick_132

Reichstein fa

Reichstein's substance fa

Reichstein's substance Fa

Scheroson

Solu-cortef

Stie-cort

Texacort

Westcort

Wintersteiner's compound F

δ(4)-pregnene-17a,21-diol-3,11,20-trione

δ(4)-pregnene-17α,21-diol-3,11,20-trione

Pharmaceutical Solutions

Phase 1, Phase 2,Not Applicable

Sympathomimetics

Phase 1, Phase 2

Respiratory System Agents

Phase 1, Phase 2

Adrenergic beta-Agonists

Phase 1, Phase 2

Antineoplastic Agents, Hormonal

Phase 1, Phase 2

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 1, Phase 2

Hormones

Phase 1, Phase 2

Adrenergic Agonists

Phase 1, Phase 2

Anti-Inflammatory Agents

Phase 1, Phase 2

Hormone Antagonists

Phase 1, Phase 2

Prednisolone acetate

Phase 1, Phase 2

Peripheral Nervous System Agents

Phase 1, Phase 2

Bronchodilator Agents

Phase 1, Phase 2

Gastrointestinal Agents

Phase 1, Phase 2,Phase 2

Neuroprotective Agents

Phase 1, Phase 2

Autonomic Agents

Phase 1, Phase 2

Anti-Asthmatic Agents

Phase 1, Phase 2

Antiemetics

Phase 1, Phase 2

glucocorticoids

Phase 1, Phase 2

Neurotransmitter Agents

Phase 1, Phase 2

Adrenergic Agents

Phase 1, Phase 2

Protective Agents

Phase 1, Phase 2

Cardiotonic Agents

Phase 1, Phase 2

Methylprednisolone acetate

Phase 1, Phase 2

Cholagogues and Choleretics

Phase 2,Phase 1

Endothelial Growth Factors

Mitogens

Interventional clinical trials:

(show all 15)

#	Name	Status	NCT ID	Phase	Drugs
1	A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma	Completed	NCT01613313	Phase 2	Collagenase Clostridium Histolyticum
2	Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma	Completed	NCT02249052	Phase 2	AA4500;placebo
3	Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas	Completed	NCT00624416	Phase 1, Phase 2	Prednisolone synthetic cortisone and Isoproterenol together
4	Phase 2 Study for the Treatment of Superficial Lipomas	Completed	NCT00608842	Phase 2	Deoxycholic Acid Injection;Placebo
5	Evaluation of Safety and Efficacy of RZL-012 for the Treatment of Lipedema or of Nodular Dercum's Disease	Recruiting	NCT03492840	Phase 2	RZL-012
6	Deoxycholic Acid Injection for the Treatment of Superficial Lipomas	Completed	NCT00422188	Phase 1	Deoxycholic Acid Injection;Placebo
7	Developing a Biomarker for Monitoring Clinical Outcomes in Children With Spinal Lipoma.	Unknown status	NCT02722681
8	Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning	Unknown status	NCT00671385
9	Ultra-sounded Guided Regional Blockade for Lipoma Excision	Completed	NCT02753361	Not Applicable
10	Periampullary Lesions Via ERCP in Assuit University Hospital	Recruiting	NCT03185390	Not Applicable
11	Pilot Study of Infrared Imaging of Cutaneous Melanoma	Completed	NCT00937690
12	Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors	Completed	NCT02884154	Not Applicable
13	Insight Into Subcutaneous Adipose Tissue Disorders	Recruiting	NCT02838277
14	Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions	Recruiting	NCT02638935	Not Applicable
15	Identification of Biomarkers for Patients With Vascular Anomalies	Recruiting	NCT03001180

Search NIH Clinical Center for Lipomatosis, Multiple

Cochrane evidence based reviews: neoplasms, adipose tissue

Sources

Genetic Tests for Lipomatosis, Multiple

Genetic tests related to Lipomatosis, Multiple:

#	Genetic test	Affiliating Genes
1	Lipoma ²⁹
2	Lipomatosis, Multiple ²⁹

Sources

Anatomical Context for Lipomatosis, Multiple

MalaCards organs/tissues related to Lipomatosis, Multiple:

⁴¹

Colon, Skin, Bone, Spinal Cord, Tongue, Liver, Kidney

Sources

Publications for Lipomatosis, Multiple

Articles related to Lipomatosis, Multiple:

(show top 50) (show all 573)

#	Title	Authors	Year
1	Spindle cell lipoma mimicking pleomorphic adenoma: A diagnostic challenge on cytology. ( 30468314 )	Kaur M...Saini V	2018
2	Tubular adenoma overlying a colonic lipoma resected by endoscopic mucosal resection using detachable endoloop. ( 30503845 )	Chu SJ...Kim BW	2018
3	Lipoma of the transverse colon covered by tubulovillous adenoma: a rare indication for surgical treatment. ( 29549684 )	Moschetta M...Stabile Ianora AA	2018
4	Intussusception secondary to descending colon lipoma presenting with simultaneous acute appendicitis. ( 29992005 )	Kikuchi N...Rikiyama T	2018
5	Coincidence of Tethered Cord, Filum Terminale Lipoma, and Sacral Dural Arteriovenous Fistula: Report of Two Cases and a Literature Review. ( 30319536 )	Przepi?rka ?...Marchel A	2018
6	Carpal Tunnel Syndrome Caused by Intraneural Lipoma of the Median Nerve and Arteriovenous Malformation. ( 29731590 )	Aydin A	2018
7	Capillary hemangioma involved in filar lipoma: A case report. ( 30309451 )	Naruke Y...Ando R	2018
8	Obesity and pericallosal lipoma in X-linked emery-dreifuss muscular dystrophy: A case report - Does Emerin play a role in adipocyte differentiation? ( 30079154 )	Spanu F...Saba L	2018
9	Endobronchial lipoma with tuberculosis: A solitary coetaneousness. ( 29319046 )	Bansal S...Joshi JM	2018
10	Pericallosal Lipoma and Cortical Dysplasia Masquerading as a Glioma. ( 30083489 )	Anderson BL...Thamburaj K	2018
11	Complete small bowel obstruction without intussusception due to a submucosal lipoma. ( 29992008 )	Konik RD...Rhodes RA	2018
12	Colonic intussusception caused by a sigmoidal lipoma: A case report. ( 30059860 )	M'rabet S...Jazia EB	2018
13	Pedunculated small bowel lipoma with heterotopic pancreas causing intussusception. ( 30214784 )	Papageorge M...Yoo J	2018
14	Laparoscopic segmental resection of the rectum for upper rectal intussusception caused by a giant rectal lipoma: A case report. ( 30278497 )	Wei R...Mao S	2018
15	Intussusception of colonic lipoma with ischaemic necrosis: a new colonoscopic finding. ( 30294849 )	Huang HY...Yen HH	2018
16	Ileoileal and ileocecal intussusception due to ileal lipoma: A rare cause of bowel obstruction in the adult. ( 28684032 )	V?zquez R...Toscano E	2018
17	An intraspinal extradural lipoma with spinal epidural lipomatosis: A case report and a review of literature. ( 30488010 )	Tateiwa D...Wada E	2018
18	Liposarcoma of the spermatic cord associated with scrotum lipoma: A case report and review of the literature. ( 29541595 )	Yamamichi G...Tsujihata M	2018
19	Liposarcoma Preoperatively Diagnosed as Lipoma: 10-Year Experience at a Single Institution. ( 29659409 )	Sato D...Takushima A	2018
20	Successful removal of giant mediastinal lipoma and liposarcoma involving both chest cavities: Two case reports. ( 30095647 )	Chen C...Yu F	2018
21	Fatty tumors of the retroperitoneum: Lipoma or well-differentiated liposarcoma. About a case of a giant retroperitoneal liposarcoma. ( 30211007 )	Bibi M...Nouira Y	2018
22	Multiple well-differentiated cardiac liposarcoma with a concomitant myocardial lipoma: A case report. ( 30546890 )	Kong F...Guo Q	2018
23	Immunohistochemical differentiation between spindle cell lipoma and neurofibroma of oral cavity using CD34 and SOX10. ( 30303149 )	Bajpai M...Kumar M	2018
24	Simultaneous Median and Ulnar Compression Neuropathy Secondary to a Giant Palmar Lipoma: A Case Report and Review of the Literature. ( 29666776 )	Unal M...Kose O	2018
25	Pleural lipoma presenting with back pain. ( 27323307 )	Kermenli T...Ekiz T	2018
26	Transient Anarthria and Quadriplegia in a Patient with Basilar Artery Hypoplasia and Coincidental Intracranial Lipoma: A Case Report. ( 30519181 )	Jung KO...Park JH	2018
27	Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma. ( 30001242 )	Michal M...Fetsch JF	2018
28	Giant bipolar intramedullary nondysraphic spinal cord lipoma: A case report. ( 30396693 )	Kouadria R...Mhamdi C	2018
29	Intramedullary Spinal Cord Lipoma Mimicking a Late Subacute Hematoma. ( 30459918 )	Pasalic I...Mrak G	2018
30	Low-fat, plexiform spindle cell lipoma of the lip expressing S100 protein: a neural tumor simulator. ( 29940654 )	Val-Bernal JF...Mazorra R	2018
31	Pericallosal lipoma masquerading as venous thrombosis on magnetic resonance imaging. ( 30504604 )	Jakkani RK...Ramineni KK	2018
32	Gastrointestinal: Gastric lipoma as a rare cause of recurrent gastrointestinal bleeding. ( 29542245 )	Yen HH...Chen CJ	2018
33	Giant pericallosal lipoma presenting with psychosis. ( 29547194 )	Li Y...Fan F	2018
34	Cardiac Lipoma: An Uncharacteristically Large Intra-Atrial Mass Causing Symptoms. ( 29552360 )	Naseerullah FS...Murthy A	2018
35	Medical image analysis of knee joint lipoma arborescens and arthroscopic treatment. ( 29567561 )	Zhu G...Zheng X	2018
36	Simvastatin induces apoptosis in PTEN‑haploinsufficient lipoma cells. ( 29568880 )	K?ssner F...Garten A	2018
37	A case of junctional neural tube defect associated with a lipoma of the filum terminale: a new subtype of junctional neural tube defect? ( 29600904 )	Florea SM...Scavarda D	2018
38	Preoperative radiologic patent blue localization for intracorporeal laparoscopic resection of a terminal ileal submucosal lipoma: A case report. ( 29604532 )	Wu HY...Yu MC	2018
39	Accessory scrotum and congenital perineal lipoma in a child with type 2 congenital pulmonary airway malformation: A report of an unusual. ( 29623024 )	Fathaddin AA	2018
40	Frontal subcutaneous lipoma associated with interhemispheric lipoma, lipomeningocele, and corpus callosal dysgenesis in a young adult: CT and MRI findings. ( 29692522 )	Aggarwal N...Khan NKA	2018
41	An Incidental Periscapular Lipoma With Marked Bone Erosion in an Elderly Woman With Contralateral Shoulder Pain. ( 29705170 )	Koyuncu EG...?z?akar L	2018
42	Para-anal lipoma as a rare consequence to perineal trauma. Case-report and review of the literature. ( 29734868 )	Uscilowska E...Kartheuser A	2018
43	A Large Size Lipoma at Spinoglenoid Notch Mimicked Traumatic Rotator Cuff Tear. ( 29734906 )	Kim JY...Cho JH	2018
44	A case report of multi-compartmental lipoma of the hand. ( 29736408 )	Bocchiotti MA...Pozzi A	2018
45	Thoracoscopic resection of parosteal lipoma of the rib using orthopedic electric micro drill. ( 29744749 )	Go T...Yokomise H	2018
46	Noninvasive size reduction of lipoma with an insulated monopolar radiofrequency microneedle device. ( 29744986 )	Hong JY...Kim BJ	2018
47	Retropharyngeal lipoma presenting with snoring in a child. ( 29752203 )	Jin SM...Lim SC	2018
48	Giant ileocecal submucosal lipoma presenting with hematochezia. ( 29752793 )	Yagnik VD	2018
49	Intralesional Injection of Triamcinolone Acetonide for Subcutaneous Lipoma causing Musculoskeletal and Neurologic Symptoms. ( 29785238 )	Hayward WA...Kettwich SK	2018
50	A Rare Case of Incidental Tracheal Lipoma. ( 29803520 )	Rotolo N...Imperatori A	2018

Sources

Genes for Lipomatosis, Multiple

Genes related to Lipomatosis, Multiple (0 elite genes):

(show all 13)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	HMGA2	High Mobility Group AT-Hook 2	Protein Coding	28.4	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	18663748 19431195 10329012 (more) 12781451 9212729 15755872 19528502 10744071 9772904 18383898 9403060 8889500 16375854 10519386 7606786 17372913 8824803 9244875 10472377 8637707 12970064 17045619 19837271 19433298 15202015 9495195 19963137 14603445 11566348 10727978 10824997 12063392 11391797 10747931 9598796 9466569 19346081 12021922 10998430 10637295 18381458 17332316 9696033 16133369 14612541 16276091 11921278 17370328 11576996 12206982 15882911 8791483
2	MDM2	MDM2 Proto-Oncogene	Protein Coding	24.58	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	14694526 11518050 9071998 (more) 7519048 7591308 18779733 10755400 9703873 15242313 10727978 17372913 7656201 19820690
3	LPP	LIM Domain Containing Preferred Translocation Partner In Lipoma	Protein Coding	23.86	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9772904 10637295 9598796
4	CDK4	Cyclin Dependent Kinase 4	Protein Coding	23.21	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	14694526 10755400 10727978 (more) 20063101 15154619 9703873 17372913
5	MEN1	Menin 1	Protein Coding	22.85	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	19596783 11381507 11571558
6	HMGA1	High Mobility Group AT-Hook 1	Protein Coding	22.26	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9212729 10744071 12970064 (more) 9187132 10472377 9824199 8824803 17370328
7	FUS	FUS RNA Binding Protein	Protein Coding	22.01	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9244875
8	PTEN	Phosphatase And Tensin Homolog	Protein Coding	20.33	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	15920539 16952599 17526800 (more) 9832032 10400993 10749983 11571558
9	DES	Desmin	Protein Coding	17.18	Novoseek inferred ⁵⁵	15322874 9331894 17585537
10	ALX3	ALX Homeobox 3	Protein Coding	16.43	DISEASES inferred ¹⁵
11	LHFPL6	LHFPL Tetraspan Subfamily Member 6	Protein Coding	16.11	DISEASES inferred ¹⁵
12	MNX1	Motor Neuron And Pancreas Homeobox 1	Protein Coding	15.95	DISEASES inferred ¹⁵
13	UCP1	Uncoupling Protein 1	Protein Coding	15.49	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	11095987 8468458

Sources

Variations for Lipomatosis, Multiple

Copy number variations for Lipomatosis, Multiple from CNVD:

⁷

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	173076	3	189413414	190080135	Translate	LPP	Lipoma

Sources

Expression for Lipomatosis, Multiple

Search GEO for disease gene expression data for Lipomatosis, Multiple.

Sources

Pathways for Lipomatosis, Multiple

Pathways related to Lipomatosis, Multiple according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	11.88	CDK4 MDM2 PTEN
2	Chromatin Regulation / Acetylation ⁴	11.86	FUS HMGA1 HMGA2 MEN1
3	AKT Signaling Pathway ⁶⁷	11.79	CDK4 MDM2 PTEN
4	Cellular senescence (KEGG) ³⁷	11.78	CDK4 MDM2 PTEN
5	Integrated Breast Cancer Pathway ¹	11.73	CDK4 MDM2 PTEN
6	Glioblastoma Multiforme ⁶⁴	11.54	CDK4 MDM2 PTEN
7	Transcriptional misregulation in cancer ³⁷	11.53	FUS HMGA2 MDM2 MEN1
8	Senescence and Autophagy in Cancer ¹	11.46	HMGA1 MDM2 PTEN
9	Oncogene Induced Senescence ⁶⁶	10.98	CDK4 MDM2
10	Integrated Cancer Pathway ¹	10.46	CDK4 MDM2 PTEN

Sources

GO Terms for Lipomatosis, Multiple

Cellular components related to Lipomatosis, Multiple according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleus	GO:0005634	9.7	ALX3 CDK4 DES FUS HMGA1 HMGA2
2	chromatin	GO:0000785	9.33	CDK4 HMGA2 MEN1
3	senescence-associated heterochromatin focus	GO:0035985	8.62	HMGA1 HMGA2

Biological processes related to Lipomatosis, Multiple according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of transcription, DNA-templated	GO:0045892	9.71	HMGA1 HMGA2 MDM2 MEN1
2	negative regulation of cell cycle arrest	GO:0071157	9.37	CDK4 MDM2
3	cellular response to peptide hormone stimulus	GO:0071375	9.32	MDM2 MEN1
4	positive regulation of cellular senescence	GO:2000774	9.26	HMGA1 HMGA2
5	obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle	GO:0031658	9.16	CDK4 PTEN
6	senescence-associated heterochromatin focus assembly	GO:0035986	8.96	HMGA1 HMGA2
7	oncogene-induced cell senescence	GO:0090402	8.62	HMGA1 HMGA2

Molecular functions related to Lipomatosis, Multiple according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ionotropic glutamate receptor binding	GO:0035255	9.32	FUS PTEN
2	retinoid X receptor binding	GO:0046965	9.26	FUS HMGA1
3	peroxisome proliferator activated receptor binding	GO:0042975	9.16	HMGA1 MDM2
4	DNA-(apurinic or apyrimidinic site) endonuclease activity	GO:0003906	8.96	HMGA1 HMGA2
5	AT DNA binding	GO:0003680	8.62	HMGA1 HMGA2

Sources

Sources for Lipomatosis, Multiple

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Lipomatosis, Multiple (FML)

Aliases & Classifications for Lipomatosis, Multiple

MalaCards integrated aliases for Lipomatosis, Multiple:

Characteristics:

OMIM:

HPO:

Classifications:

External Ids:

Summaries for Lipomatosis, Multiple

Related Diseases for Lipomatosis, Multiple

Diseases in the Lipomatosis family:

Diseases related to Lipomatosis, Multiple via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Lipomatosis, Multiple:

Symptoms & Phenotypes for Lipomatosis, Multiple

Symptoms via clinical synopsis from OMIM:

Clinical features from OMIM:

Human phenotypes related to Lipomatosis, Multiple:

MGI Mouse Phenotypes related to Lipomatosis, Multiple:

Drugs & Therapeutics for Lipomatosis, Multiple

FDA approved drugs:

Drugs for Lipomatosis, Multiple (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Cochrane evidence based reviews: neoplasms, adipose tissue

Genetic Tests for Lipomatosis, Multiple

Genetic tests related to Lipomatosis, Multiple:

Anatomical Context for Lipomatosis, Multiple

MalaCards organs/tissues related to Lipomatosis, Multiple:

Publications for Lipomatosis, Multiple

Articles related to Lipomatosis, Multiple:

Genes for Lipomatosis, Multiple

Genes related to Lipomatosis, Multiple (0 elite genes):

Variations for Lipomatosis, Multiple

Copy number variations for Lipomatosis, Multiple from CNVD:

Expression for Lipomatosis, Multiple

Pathways for Lipomatosis, Multiple

Pathways related to Lipomatosis, Multiple according to GeneCards Suite gene sharing:

GO Terms for Lipomatosis, Multiple

Cellular components related to Lipomatosis, Multiple according to GeneCards Suite gene sharing:

Biological processes related to Lipomatosis, Multiple according to GeneCards Suite gene sharing:

Molecular functions related to Lipomatosis, Multiple according to GeneCards Suite gene sharing:

Sources for Lipomatosis, Multiple